Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.

Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.

2.

Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Lancet Oncol. 2007 Jan;8(1):26-34.

PMID:
17196508
3.

Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.

Duffy DL, Antill YC, Stewart CJ, Young JP; kConFab, Spurdle AB.

Twin Res Hum Genet. 2011 Apr;14(2):111-8. doi: 10.1375/twin.14.2.111.

PMID:
21425892
4.

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA.

J Clin Oncol. 2005 Oct 20;23(30):7491-6.

PMID:
16234515
5.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.

JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.

PMID:
26181175
6.

Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1089-96. doi: 10.1158/1055-9965.EPI-12-0201. Epub 2012 May 7.

7.

The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Gynecol Oncol. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3.

PMID:
23562522
8.

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group.

Lancet. 2000 Dec 2;356(9245):1876-81.

PMID:
11130383
9.

The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.

Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, Jacobs IJ.

Lancet Oncol. 2013 Nov;14(12):1226-32. doi: 10.1016/S1470-2045(13)70448-0. Epub 2013 Oct 17.

10.

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.

PMID:
28802188
11.

Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.

Reitsma W, Mourits MJ, de Bock GH, Hollema H.

Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.

12.

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.

J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

13.

Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.

Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J.

Fertil Steril. 2015 May;103(5):1305-12. doi: 10.1016/j.fertnstert.2015.02.011. Epub 2015 Mar 16.

PMID:
25792249
14.

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2015 Sep 1;137(5):1136-46. doi: 10.1002/ijc.29386. Epub 2014 Dec 18.

15.

Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.

Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative Group.

Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.

16.

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.

Cibula D, Zikan M, Dusek L, Majek O.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1197-207. doi: 10.1586/era.11.38.

PMID:
21916573
17.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

18.

Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.

Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E.

Breast Cancer Res Treat. 2011 Sep;129(2):557-63. doi: 10.1007/s10549-011-1509-z. Epub 2011 Apr 16.

PMID:
21499684
19.

Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P; Hereditary Breast Cancer Clinical Study Group.

Lancet Oncol. 2006 May;7(5):402-6. Erratum in: Lancet Oncol. 2006 Jun;7(6):453. Domcheck, Susan [corrected to Domchek, Susan].

PMID:
16648044
20.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

Supplemental Content

Support Center